New Combination Treatment Options for Non-Small Cell Lung Cancer
Trial Objectives
Researchers with the national COPERNICUS study are evaluating an investigational combination of treatments that may be able to help better target advanced non-small lung cancer with specific gene mutations. The results of the study will help improve treatments for people with lung cancer in the future.Participants with advanced non-small cell lung cancer with EGFR mutations will be assigned to a combination of an injected study medication and an oral treatment. Study volunteers will be assigned to the treatment group and will be monitored for tumor response, changes in their health and side effects. They also will receive blood tests and imaging as needed to monitor their health.
Who Can Participate
Adults with advanced or metastatic non-small cell lung cancer and either an Ex19del or Ex21 L858R substitution mutation in the EGFR gene, confirmed by a laboratory test. Enrollment in the study is by invitation only.
Age: 18+ Gender: Any
Estimated Time Commitment
Up to 36 months, with 20 clinic visits over the first year, one visit every three weeks for a follow up period, and a finalization period with a visit every 12 weeks until the conclusion of the study.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Janssen Research and Development
Principal Investigators
Laurie L. Carr, MD